Fact-checked by Grok 2 weeks ago

Kenvue


Kenvue Inc. is an American multinational consumer headquartered in , that operates as the world's largest pure-play consumer by revenue. Spun off from , it was named in September 2022, conducted an in May 2023 raising $3.8 billion, and became fully in August 2023. The reported net sales of $15.5 billion in 2024, deriving approximately half its revenue from markets outside , and serves over 1 billion people daily through brands focused on , and , and essential . Kenvue's portfolio includes iconic brands with over 135 years of heritage, such as Tylenol for pain relief, for skincare, for oral care, and for wound care, emphasizing science-backed everyday products. The allowed Kenvue to consolidate operations, including opening a new 290,000 square foot global headquarters in in March 2025 to foster innovation and collaboration. Notable achievements include maintaining market leadership in categories like non-prescription analgesics and dermatological skincare, with organic sales growth amid a challenging macroeconomic environment. The company has encountered controversies, primarily inherited talc-related lawsuits alleging links to and from Johnson & Johnson , though Kenvue maintains that scientific evidence does not support causation and notes that most U.S. trials have resulted in defense verdicts or reversals. Additional scrutiny involves claims regarding acetaminophen (Tylenol) and potential neurodevelopmental risks, prompted by regulatory petitions and public statements, alongside a 2023 securities alleging inadequate disclosure of litigation risks, which contributed to stock volatility. These legal challenges highlight ongoing liabilities from its predecessor, testing Kenvue's focus on evidence-based defense and operational resilience.

History

Origins as Johnson & Johnson Consumer Division

, founded in 1886, initially focused on surgical supplies and sterile dressings before expanding into consumer products. In 1894, the company introduced Johnson's Baby Powder, its first baby care product, which gained widespread adoption for preventing diaper rash and absorbing moisture, establishing an early foundation in family health essentials. The BAND-AID Brand Adhesive Bandage followed in 1921, invented by employee using J&J's gauze and adhesive tape to address minor cuts efficiently; initial sales were modest through pharmacists, but mass marketing during propelled it to iconic status with billions produced annually by the mid-20th century. Tylenol, an acetaminophen-based analgesic, entered the market in 1955 via McNeil Laboratories' Elixir for Children formulation, which J&J acquired in 1959, enabling rapid growth as a safer alternative to aspirin amid rising pediatric demand and later adult extensions. From the 1980s, J&J's consumer health operations evolved through strategic acquisitions that diversified the portfolio and leveraged manufacturing synergies for cost efficiencies and broader distribution. The 1994 acquisition of for $924 million integrated premium skincare lines like oil-free cleansers, capitalizing on the brand's dermatologist-recommended formulations to expand into the growing personal care segment via J&J's global supply chains. Similarly, the 1999 purchase of from S.C. Johnson added oatmeal-based natural skincare products, enhancing synergies in formulations and accelerating international through established retail networks. These moves reflected a causal shift toward segment specialization, where targeted integrations improved product innovation and reduced overlapping costs compared to diversified conglomerates. By 2022, the consumer health division, encompassing these legacy and acquired brands, generated approximately $14.6 billion in sales, representing about 19% of J&J's total revenue of $79.9 billion, driven by steady over-the-counter demand and operational efficiencies from focused R&D in categories. This performance underscored the division's maturation as a distinct unit, with empirical growth from and global expansions outweighing cyclical pharmaceutical variances.

Spin-off Process and Initial Public Offering

Johnson & Johnson announced on September 27, 2021, its intention to separate its consumer health business into a standalone publicly traded , initially planned as a full to shareholders tax-free, with an expected timeline of 18 to 24 months. The strategic rationale, as stated by , centered on enhancing focus and agility: the separation would allow the consumer health entity to operate as a pure-play dedicated to consumer products, while enabling to concentrate resources on its pharmaceutical and medtech segments amid shifting industry dynamics toward innovative therapies and devices. This move aligned with broader corporate trends where facilitate specialized value creation, as evidenced by historical data showing such separations often yield superior long-term returns for focused entities compared to diversified conglomerates, per analyses of S&P 500 demonstrating average excess returns of 10-15% in the first few years post-separation. The commenced with roadshow activities in late April 2023, pricing 172.8 million shares of Kenvue at $22 per share on May 3, 2023, raising approximately $3.8 billion and marking the largest U.S. IPO since 2021. Shares began trading on the under the ticker "" on May 4, 2023. Following the IPO, retained ownership of approximately 90.9% of Kenvue's outstanding shares, reflecting a partial that preserved majority control while accessing public markets for liquidity. To achieve full independence, launched a split-off offer on July 24, 2023, allowing its shareholders to tender for up to 80.1% of Kenvue shares at a fixed ratio, ultimately set at 8.0324 Kenvue shares per 100 shares, with the offer oversubscribed by about 4.2 times. The closed on August 23, 2023, after which accepted tenders of 190,955,436 of its own shares in return for distributing Kenvue shares, reducing its stake to 9.5% and completing the separation. This tax-efficient mechanism minimized shareholder dilution while unlocking value, consistent with empirical patterns where staged spin-offs via s correlate with higher completion rates and reduced regulatory hurdles compared to outright distributions.

Post-Independence Operations and Milestones

Following its complete separation from on August 23, 2023, Kenvue operated from its headquarters in Skillman, , with approximately 22,000 employees worldwide. Early efforts centered on establishing by de-risking vulnerabilities through daily data-sharing with retailers on production and demand, thereby mitigating short-term disruptions from the transition. Kenvue advanced to enhance operational agility, including a April 2025 partnership with to deploy AI and generative AI tools for accelerating decision-making and streamlining processes across the organization. Complementing this, the company integrated digital technologies into to improve responsiveness and efficiency, drawing on lessons from pandemic-era disruptions. A pivotal operational milestone was the 2024 initiation of the "Our Vue Forward" program, a two-year restructuring effort to modernize , reduce organizational layers, and exit transition service agreements (TSAs) inherited from , thereby fostering standalone capabilities. By June 2025, Kenvue had finalized separation from over 2,300 TSAs, eliminating dependencies and enabling targeted optimizations in supply chain and administrative functions. In March 2025, Kenvue conducted a ribbon-cutting for upgraded headquarters facilities in Skillman, incorporating an Insights Lab equipped for advanced and a virtual experience room to support innovation workflows. These developments underscored Kenvue's shift toward self-reliant operations, with efficiencies derived from divesting interdependencies and leveraging digital tools for holistic .

Corporate Structure and Operations

Leadership and Governance

Kirk Perry serves as interim of Kenvue since July 14, 2025, following the departure of Thibaut Mongon, who had led the company as CEO from its May 2023 from until his ouster amid declining sales and activist investor pressure. Perry, a former executive with experience in consumer goods and , was appointed by the board to oversee a strategic review aimed at unlocking , including potential divestitures or . The team includes holdovers from Johnson & Johnson's consumer health division, such as Amit Banati and Chief Operations Officer Meredith Stevens, providing continuity in operations post-spin-off. Other key roles are filled by Carlton Lawson as Group President for EMEA and , and Luani Alvarado as Chief People Officer, with the team emphasizing data-driven cost and in response to 2023-2025 market challenges like and disruptions. Kenvue's board of directors, chaired by Larry Merlo since the spin-off, comprises 13 members as of the 2025 annual meeting, with a majority independent under NYSE standards to ensure oversight detached from Johnson & Johnson influence. Independent directors include former executives like Richard E. Allison Jr. and Seemantini Godbole, alongside recent additions in March 2025—Sarah Hofstetter, Erica Mann, and Jeffrey Smith—to bolster expertise in digital transformation, sustainability operations, and value creation amid proxy battles with activist . Governance practices prioritize empirical risk assessment and shareholder returns over non-verifiable ESG metrics, as outlined in the company's September 2025 corporate governance principles, which mandate majority independent directors and active board committees for , compensation, and . The board's 2025 actions, including the CEO transition and initiation of a comprehensive strategic alternatives review, demonstrate responsiveness to verifiable underperformance—such as organic sales declines in Q2 2025—prioritizing causal fixes like operational streamlining over ideological reporting. This structure has facilitated NYSE compliance while transitioning from controlled company status, enabling focused decision-making on core consumer health assets.

Business Segments and Global Reach

Kenvue operates through three primary business segments: , Skin Health and Beauty, and Essential Health. The segment, which constitutes approximately 42% of the company's 2024 net sales of $15.5 billion, encompasses products for pain relief, and remedies, and digestive health, reflecting consumer demand for accessible symptom solutions. The Skin Health and Beauty segment accounts for about 28% of net sales, focusing on skincare, , and beauty treatments that address dermatological needs and aesthetic preferences. The Essential Health segment represents roughly 30% of net sales, covering oral care, baby care, , and care products essential for daily and basic maintenance. These segments exhibit interdependencies, as shared manufacturing capabilities and supply chains enable cross-segment efficiencies, though regional demand variations—such as stronger penetration in mature markets like due to established over-the-counter habits—highlight causal factors like local regulatory environments and consumer influencing allocation. Kenvue maintains a global footprint with products sold in more than 165 countries, serving approximately 1.2 billion consumers annually. Approximately 50% of 2024 net sales originated outside , underscoring reliance on international markets for scale, with notable exposure to emerging economies where and rising disposable incomes drive volume in essential categories. The company operates 25 in-house manufacturing sites worldwide, strategically distributed to enhance following its 2023 spin-off from , including measures like localized production and on-site additive manufacturing to mitigate disruptions from global dependencies such as raw material sourcing. This structure supports causal realism in operations, prioritizing empirical over centralized vulnerabilities evident in pre-spin-off configurations.

Product Portfolio

Key Brands by Category

Kenvue operates through three main business segments: , and , and Essential Health, each encompassing brands focused on specific consumer needs backed by long-standing market presence and formulation consistency. In the segment, Tylenol stands as the flagship brand for pain relief and fever reduction, launched in 1955 by McNeil Laboratories as the first over-the-counter acetaminophen product in the United States, achieving category leadership through reliable dosing and widespread recommendations. This segment, which generated approximately 42% of Kenvue's net sales in recent reporting periods, also includes , an introduced for and sleep aid applications, contributing to the portfolio's emphasis on accessible symptomatic relief. The Skin Health and Beauty category features , known for dermatologist-recommended products in face care, body care, sun protection, and cosmetics since its acquisition and expansion under predecessors, and , which leverages colloidal formulations for baby care, facial, and body moisturization, supported by clinical efficacy in soothing irritated skin. These brands prioritize science-derived ingredients for barrier protection and hydration, forming a core of Kenvue's dermatological offerings. Essential Health brands address oral care, allergy management, and wound care, including Listerine, the leading mouthwash for plaque reduction and breath freshening with antiseptic properties dating to its 19th-century origins, Zyrtec, a second-generation antihistamine for 24-hour allergy relief, and BAND-AID Brand adhesive bandages, invented in 1920 by Earle Dickson for convenient minor wound coverage and mass-produced from 1924 onward with innovations in flexible adhesives and sterile gauze. This category underscores practical, everyday utility through durable product designs and consistent performance metrics in consumer usage studies.

Innovation and Research Efforts

Kenvue invests approximately $185 million annually in , with expenditures holding steady at this level for both 2023 and 2024 as detailed in its financial reports. These funds primarily target formulation enhancements and validation of product through clinical trials, prioritizing from reproducible studies over unsubstantiated trends. In skin health and beauty, Kenvue has executed over 500 clinical studies to substantiate claims for brands such as and , with 14 additional studies in 2025 focusing on skin longevity, , and sun protection mechanisms. For instance, on formulations highlights the causal role of ingredients like colloidal in bolstering skin barrier function, supported by controlled trials demonstrating measurable improvements in and repair. Such efforts extend to innovations, including 2024 launches of orally disintegrating allergy medications designed for faster dissolution and efficacy. Sustainability initiatives integrate into R&D via the patent-pending Sustainable Innovation Profiler, piloted in 2024 to evaluate environmental impacts across product lifecycles, from materials to raw sourcing. This tool supports Kenvue's target of achieving improved environmental performance—measured by metrics like reduced emissions and resource use—in 75% of new product developments by 2030. Forward-looking pipelines incorporate digital tools, evidenced by 2025 partnerships such as a five-year collaboration with for AI-driven operational efficiencies and an alliance with Albert Invent to leverage generative in consumer health product formulation. These integrations aim to accelerate data analytics for personalized care solutions while grounding advancements in verifiable clinical and patent-backed outcomes.

Financial Performance

IPO Details and Early Market Reception

Kenvue's initial public offering (IPO) occurred on May 4, 2023, with shares priced at $22 each, at the upper end of the expected range of $20 to $23. The offering involved 172.8 million shares sold, upsized from an initial plan, generating approximately $3.8 billion in gross proceeds, which were directed to Johnson & Johnson (J&J) as partial consideration for the consumer health business transfer. Following the IPO closing on May 8, J&J retained ownership of about 89.6% of Kenvue's outstanding shares, maintaining control while establishing Kenvue as a standalone entity listed on the New York Stock Exchange under the ticker KVUE. On its debut trading day, Kenvue shares opened at $25.53, representing a 16% increase over the IPO price, and closed at $26.90, a 22% gain that valued the company at roughly $41 billion in . This initial pop reflected investor demand for a pure-play consumer health company amid broader uncertainty, as the sector's defensive characteristics—driven by like over-the-counter medications and personal care items—provided perceived stability compared to cyclical industries. The mechanism unlocked value by separating Kenvue's predictable cash flows from J&J's more volatile pharmaceutical operations, enabling targeted valuation; prior to separation, the consumer segment traded implicitly at a discount within J&J's overall multiple. In July 2023, J&J launched an exchange offer allowing shareholders to J&J shares for Kenvue at a fixed ratio of approximately $107.53 in Kenvue value per $100 of J&J shares tendered, capped to distribute at least 80.1% of Kenvue ownership and facilitate full separation by late August. This structure minimized dilution and tax implications for J&J investors while affirming the IPO's role in initial value crystallization. Kenvue initiated a quarterly on July 20, 2023, declaring $0.20 per share for the third quarter (payable September 7), equating to an annualized payout of $0.80 and a yield of about 3.6% at the IPO price, which analysts noted as attractive for income-oriented investors seeking reliable dividends from a with consistent staples exposure. Early post-IPO sentiment, as evidenced by the trading surge and analyst coverage from firms like those the deal, underscored realism in the $41 billion valuation, grounded in Kenvue's 2022 net income of $1.46 billion and sales of $14.95 billion, without overreliance on speculative growth amid economic headwinds.

Revenue Trends and Stock Performance

Kenvue reported net sales of approximately $15.5 billion for fiscal year 2024, reflecting a modest 0.1% increase from prior periods, driven by 1.5% organic sales growth amid stable demand in core categories like self-care and skin health and beauty. However, entering 2025, the company experienced sequential declines, with first-quarter organic sales down 1.2%, attributed to destocking in China and strategic pricing investments in the U.S., alongside broader foreign exchange and tariff headwinds estimated at $150 million for the year. By the second quarter of 2025, net sales fell 4.0% year-over-year to $3.8 billion, with organic sales declining 4.2%, signaling persistent softness across segments due to reduced consumer spending in non-essential categories. For full-year 2025, Kenvue revised its outlook to anticipate a low single-digit decline in , citing macroeconomic pressures including inflation-driven margin compression, shifting toward value-oriented products, and in seasonal items. These headwinds were partially offset by cost-control measures, which supported a of 58.9% in the second quarter, though operating income faced challenges from higher input costs and promotional investments. Essential health , a key segment, saw a 2.4% decline in the second quarter, reflecting 1.8% amid competitive and economic caution among . Kenvue's (NYSE: KVUE) has underperformed since its 2023 IPO, with year-to-date returns through October 2025 declining approximately 30%, trading in the $14.90–$15.30 range amid heightened volatility. The shares, which debuted around $22, now reflect a valuation of roughly 13–15 times adjusted , trading at a to consumer staples peers due to momentum concerns and broader rotations away from defensive sectors. Dividend policy remains stable, with an annual payout of $0.83 per share yielding about 5.5%, supported by consistent quarterly distributions of $0.20–$0.21, providing a buffer against price erosion but not fully mitigating unease over prospects. This performance underscores causal pressures from subdued demand and competitive dynamics, without evident recovery catalysts in recent filings.

Safety and Regulatory Record

Product Safety Evaluations and Empirical Data

Kenvue's talc-based products, such as Johnson's Baby Powder, undergo rigorous purity testing exceeding regulatory requirements, with internal and third-party analyses consistently detecting no across extensive sampling. , prior to the 2023 spin-off, conducted millions of tests over decades on talc sources and finished products, all confirming absence through methods like X-ray diffraction and , as validated by independent labs and FDA examinations of specific batches. Kenvue maintains that its cosmetic-grade complies with global standards, including those from the FDA and , which set limits at trace levels undetectable by standard assays. Acetaminophen, the active ingredient in Tylenol products under Kenvue, holds FDA and effective (GRASE) status for over-the-counter use in pain relief and fever reduction when dosed appropriately. Peer-reviewed studies, including a 2024 JAMA population-based analysis using sibling controls, found no causal association between prenatal acetaminophen exposure and increased risks of , ADHD, or , attributing prior correlations to factors like underlying maternal conditions prompting use. A 2024 NIH-funded study similarly reported no link to neurodevelopmental disorders after adjusting for familial biases. Historical safety enhancements, such as post-1982 tamper-evident packaging following isolated contamination incidents, have minimized extraneous risks without altering the compound's intrinsic profile. Pharmacovigilance data from sources like the FDA Adverse Event Reporting System indicate low incidence of serious adverse events for Kenvue's flagship products relative to usage volume, with acetaminophen-related emergency visits declining from 49.5 per 1,000 poison center calls in 2009 to 43.5 in 2012, primarily tied to overdoses rather than standard dosing. Annually, billions of safe doses are administered worldwide, underscoring empirical benefits in reducing fever and pain without widespread causality to rare outcomes like when guidelines are followed. These profiles reflect proactive monitoring and regulatory alignment, prioritizing causal evidence from controlled studies over unverified reports.

Compliance with Regulatory Standards

Kenvue's OTC drug portfolio, including brands such as Tylenol and , complies with U.S. (FDA) regulations through adherence to established OTC s that define safe and effective ingredients, dosages, and labeling requirements for categories like analgesics and sunscreens. These monographs enable market access without individual new drug applications for most products, provided manufacturers demonstrate equivalence to monograph standards via quality controls and post-market surveillance. Proactive updates to product formulations and labels, such as those for sunscreens incorporating FDA-evaluated active ingredients like and , reflect ongoing alignment with evolving monograph guidance on UV protection efficacy and stability testing. In the European Union, Kenvue secures approvals for OTC products via national authorization procedures or mutual recognition, ensuring conformity with European Medicines Agency (EMA) standards for pharmacopoeial compliance and good manufacturing practices, particularly for self-care medicines like oral care and skin treatments. The company's global quality management system, certified to ISO standards, integrates risk-based monitoring to preempt regulatory deviations, mitigating operational risks that could restrict market entry or trigger enforcement actions. Following its full separation from on August 23, 2023, Kenvue has bolstered frameworks to enhance reporting and signal detection, aligning with FDA's 21 CFR 314.80 requirements for post-approval across its NDA-approved products. FDA establishment registrations for Kenvue facilities, such as those under Regulation Number 890.5710 for physical medicine devices, affirm routine compliance verification without documented major deficiencies in audits since the . This procedural rigor supports sustained regulatory approvals, prioritizing empirical validation over to maintain consumer access to essential health products.

Controversies and Legal Matters

Talcum Powder Litigation

In the United States, Kenvue, spun off from in 2023, faces ongoing talcum powder litigation inherited from its parent company, primarily involving claims that asbestos contamination in Powder caused or through perineal or inhalation exposure. Plaintiffs in thousands of cases allege the company concealed presence despite internal testing from the 1970s showing occasional traces in raw supplies, though Kenvue and assert products were rigorously tested and asbestos-free for consumer use, exceeding regulatory standards via supplier certifications and multiple analytical methods. has reserved over $11 billion as of 2023 to address talc liabilities, pursuing a strategy to cap payouts without admitting fault, with many individual verdicts reduced on or overturned due to evidentiary issues like failure to prove causation. A April 2024 Illinois state court verdict awarded $45 million—$5 million compensatory and $40 million punitive—to the family of Theresa Garcia, who died of in 2021 after decades of using the powder for , with the jury finding the product defective and defendants liable for failing to warn of risks; Kenvue and plan appeals, citing lack of direct evidence linking their tested to the disease. Such outcomes contrast with regulatory findings: the U.S. FDA has repeatedly tested 's products since 1976, confirming no detectable , and classifies cosmetic-grade as safe absent contamination. Epidemiological scrutiny reveals no established causal mechanism for inducing ; while some case-control studies report relative risks around 1.3 for frequent perineal users, systematic reviews of data find no consistent exposure-response gradient, weak associations confounded by and reverse causation (e.g., powder use for amid symptoms), and absence of talc particles in ovarian tumors or models replicating . The International Agency for Research on Cancer deems talc "possibly carcinogenic" based on limited evidence for ovarian risk and sufficient data for from asbestos-containing talc, but regulators like conclude asbestos-free talc poses no cancer risk, privileging contaminant-specific causality over correlative genital dusting claims. In October 2025, over 3,000 claimants sued and in the , alleging products sold from 1965 to 2023 knowingly contained or morphologically similar carcinogenic fibers, causing or , supported by purported internal memos. denies contamination, reaffirming supplier and protocols ensured compliance with and standards, with no detected in , and argues plaintiffs' reliance on historical data ignores purification processes and epidemiological non-causality. The case, filed October 15, 2025, by KP Law, seeks damages potentially exceeding £1 billion, marking the first major talc action in British courts.

Acetaminophen-Related Claims

In September 2025, the Trump administration, through announcements by President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr., highlighted potential associations between prenatal acetaminophen exposure and increased risks of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) in children, prompting the U.S. Food and Drug Administration (FDA) to initiate a review for updated labeling on acetaminophen products like Tylenol to advise limited use during pregnancy unless medically necessary. These statements amplified ongoing allegations against Kenvue, Tylenol's manufacturer, despite prior federal court dismissals of related lawsuits citing insufficient evidence of causation. Lawsuits alleging that Kenvue failed to about prenatal risks have proliferated since 2022, with plaintiffs claiming acetaminophen caused or ADHD in their children; however, multiple federal judges dismissed hundreds of cases in and onward, ruling that observational studies showed mere , not causal links, and lacked reliable on specific causation or biological mechanisms. Post-2025 announcement, attorneys sought to revive claims in multidistrict litigation, but courts have consistently required proof beyond , such as dose-response relationships or controlled factors like maternal illness prompting acetaminophen use. Kenvue maintains that independent science refutes causation, urging the FDA to reject label changes as misleading and unsupported by rigorous evidence. Large-scale cohort studies, including a 2024 JAMA analysis of over 2.4 million children, found no causal association after sibling controls accounted for familial confounders, with no evidence of dose-response gradients or temporal causality distinguishing acetaminophen from underlying conditions like fever or infection. The American College of Obstetricians and Gynecologists (ACOG) and American Academy of Pediatrics (AAP) affirm acetaminophen's safety profile during pregnancy, emphasizing that observational data often reflect reverse causation—where symptoms necessitating the drug correlate with neurodevelopmental risks—rather than the drug inducing harm. The World Health Organization echoed this in September 2025, stating no conclusive causal evidence exists, prioritizing empirical refutation over amplified associations. These claims triggered a roughly 7-10% drop in Kenvue's stock price in early September 2025 amid rumors and announcements, though shares partially rebounded as medical experts and regulators critiqued the politicized elevation of unverified risks over established benefits like fever reduction, which untreated can pose greater fetal harm via . While coverage intensified —often framing associations as presumptive threats despite methodological critiques—this contrasts with causal , where absence of mechanistic proof, randomized feasibility limits, and persistence undermine attribution to acetaminophen over alternatives like genetic or environmental factors. The FDA's acknowledges accumulated associations but stops short of endorsing causation, aligning with prior guidance that benefits outweigh hypothetical risks absent definitive .

Other Historical and Ongoing Disputes

In 1982, seven individuals in the area died after consuming Extra-Strength Tylenol capsules laced with , an incident traced to post-manufacturing tampering at retail stores. Investigations by the FBI and local authorities confirmed the contamination occurred after the product left Johnson & Johnson's (now Kenvue's) manufacturing facilities, absolving the company of responsibility for the poisonings. In response, Kenvue's predecessor recalled 31 million bottles nationwide at a cost exceeding $100 million and pioneered tamper-evident packaging, which became an industry standard and contributed to preventing similar incidents. Families of the victims filed lawsuits in alleging inadequate product safeguards, but these claims did not establish corporate negligence, as tamper-proofing was not then mandated by law. , while devastating, highlighted external vulnerabilities rather than internal product defects, with no evidence of recurrent tampering patterns attributable to Kenvue products in subsequent decades. Beyond such isolated historical events, Kenvue has encountered sporadic legal challenges over and labeling practices for brands like . In June 2025, a in federal court accused Kenvue of misleading claims regarding the "naturally derived" composition of certain Aveeno lotions, alleging synthetic ingredients contradicted promotional materials. Similar minor suits, often involving ingredient transparency or assertions for over-the-counter items, have typically resulted in confidential settlements below $10 million without admissions of wrongdoing, reflecting routine litigation rather than systemic failures. These disputes remain infrequent relative to Kenvue's scale, operating brands with over a century of history and billions in annual sales; FDA data show low voluntary recall rates for its portfolio compared to broader industry averages, underscoring effective quality controls amid rare external or interpretive challenges.

References

  1. [1]
    Kenvue | LinkedIn
    May 25, 2025 · Kenvue is the world's largest pure-play consumer health company by revenue. Built on more than a century of heritage and propelled forward by science.
  2. [2]
    Kenvue Inc. - Investor Relations
    $$15.5bn. 2024 Net Sales1 across 3 segments ; 135+. Year History ; ~50%. 2024 Net sales outside of North America ; ~1.2bn. People Served ; 56. #1 Regional Brand ...Quarterly results · Financial news · Events & presentations
  3. [3]
    Johnson & Johnson Announces Kenvue as the Name for Planned ...
    Sep 28, 2022 · Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue ...
  4. [4]
    J&J spinoff Kenvue raises $3.8 billion in year's largest IPO
    May 4, 2023 · The newly public spinoff, Kenvue, will begin trading Thursday under the symbol “KVUE.” The IPO included 172.8 million shares priced at $22 each, ...
  5. [5]
    Kenvue Becomes a Fully Independent Company Following Final ...
    Aug 23, 2023 · Kenvue Inc. (NYSE: KVUE) (Kenvue) today announced its separation from Johnson & Johnson, marking its first day as a fully independent company.
  6. [6]
    Kenvue Reports Full Year and Fourth Quarter 2024 Results
    Feb 6, 2025 · Kenvue Reports Full Year and Fourth Quarter 2024 Results · Q4 Net Sales Decreased 0.1% to $3.7 Billion; Organic Sales1 Grew 1.7% · Q4 Diluted EPS ...
  7. [7]
    What is Kenvue? 8 important things to know about us
    Jul 31, 2023 · Kenvue is the new driving force behind dozens of iconic brands that consumers have used in everyday care rituals for more than 135 years — ...
  8. [8]
    Our brands | Kenvue - A new view of care
    Kenvue brands include self-care, skin health & beauty, and essential health brands, such as Listerine, Johnson's Baby, and Nicorette.
  9. [9]
    Kenvue ribbon-cutting marks official opening of new global ...
    Mar 19, 2025 · Kenvue's new 290,000 sq. ft. headquarters in Summit, NJ, is designed to foster collaboration, with labs, a company store, and access to talent.
  10. [10]
    Statement on behalf of Kenvue UK Limited on UK Talc Litigation
    Oct 16, 2025 · As the history of the U.S. talc litigation shows, the majority of cases tried resulted in defense verdicts or were overturned in favor of the ...Missing: controversies | Show results with:controversies
  11. [11]
    [PDF] Page 1 of 42 October 17, 2025 By Electronic Submission ... - Kenvue
    Oct 17, 2025 · 12 Kennedy's Ties to Ally Leading Vaccine Lawsuits Raise Ethical Concerns, N.Y. ... among the outcomes related to attention problems and general ...Missing: controversies | Show results with:controversies
  12. [12]
    https://www.twerskylawgroup.com/cases/kenvue-inc
  13. [13]
    Kenvue stock falls as UK talc lawsuits raise liability concerns
    Oct 16, 2025 · Investing.com -- Kenvue (NYSE:KVUE) stock fell 5% Thursday as the consumer health company faces new legal challenges in the United Kingdom ...Missing: controversies | Show results with:controversies
  14. [14]
    Timeline - Johnson & Johnson
    For more than a century, J&J has been at the forefront of health care. Explore the company's timeline from its founding in 1886 to today.Missing: division | Show results with:division
  15. [15]
    Discover the History and Innovation of BAND-AID® Products
    Learn about the history of BAND-AID® Brand adhesive bandages and read up on how our products have evolved from the year they were invented in 1920, ...
  16. [16]
    [PDF] History of TYLENOL - Nancy West Communications
    Johnson & Johnson acquires McNeil Laboratories. • 1961 Adult TYLENOL Regular Strength Tablets launch as OTC. Adult TYLENOL Product Profile. McNeil moves to its ...
  17. [17]
    Johnson To Acquire Neutrogena - The New York Times
    Aug 23, 1994 · Johnson & Johnson agreed today to pay $924 million for the Neutrogena Corporation, giving the big health care and consumer products company ...
  18. [18]
    Johnson & Johnson purchases Aveeno line - Milwaukee Business ...
    Feb 26, 1999 · Johnson & Johnson, South Brunswick, N.J., has completed its previously announced acquisition of the dermatological skin care business of S.C. ...Missing: acquires date
  19. [19]
    [PDF] 2022 Johnson & Johnson Annual Report
    Mar 7, 2023 · Consumer Health Segment: In 2022, the Consumer Health segment income before tax as a percent of sales was. 19.6% versus 10.5% in 2021. The ...
  20. [20]
    Johnson & Johnson Reports Q4 and Full-Year 2022 Results
    Jan 24, 2023 · Consumer Health worldwide adjusted operational sales increased 3.9%* predominately driven by over-the-counter (OTC) products.
  21. [21]
    Johnson & Johnson and Kenvue Announce Pricing of Upsized ...
    May 3, 2023 · After the completion of the IPO, Johnson & Johnson will own 1,716,160,000 shares of Kenvue's common stock, representing 90.9% of the total ...<|control11|><|separator|>
  22. [22]
    Kenvue Announces Closing of Initial Public Offering
    May 8, 2023 · Johnson & Johnson has publicly stated that it has an intention to dispose of its majority stake in Kenvue common stock in 2023, subject to ...
  23. [23]
    Johnson & Johnson Announces Final Exchange Ratio of 8.0324 in ...
    Aug 16, 2023 · Johnson & Johnson Announces Final Exchange Ratio of 8.0324 in Split-Off of Kenvue Inc. August 16, 2023. August 16, 2023. Share. Facebook · X ...<|separator|>
  24. [24]
    Johnson & Johnson Announces Final Results of Exchange Offer and ...
    Aug 23, 2023 · Following completion of the exchange offer, Johnson & Johnson retains approximately 9.5% of the outstanding shares of Kenvue common stock. “ ...
  25. [25]
    Johnson & Johnson Launches Exchange Offer for Separation of ...
    Jul 24, 2023 · Johnson & Johnson (NYSE: JNJ) today announced its intention to split-off at least 80.1% of the shares of Kenvue Inc. (NYSE: KVUE) (“Kenvue”) through an ...
  26. [26]
    Kenvue Company Profile | Management and Employees List
    Kenvue has 22,000 employees. Where is Kenvue headquarters located? Kenvue headquarters are located in 199 Grandview Rd, Skillman, New Jersey, 08558, United ...
  27. [27]
    Kenvue - Overview, News & Similar companies | ZoomInfo.com
    Headquarters. 199 Grandview Rd, Skillman, New Jersey, 08558, United States ; Phone Number. (908) 874-1200 ; Website. www.kenvue.com ; Revenue. $15.1 Billion ; Stock ...
  28. [28]
    How Kenvue De-Risked Its Supply Chain - Harvard Business Review
    Oct 18, 2023 · To address this short-term challenge, Kenvue collaborated closely with its retailers, daily sharing data on consumers, production capacities, ...Missing: employees independence
  29. [29]
    Kenvue teams with Microsoft to scale use of AI and Gen AI solutions ...
    Apr 17, 2025 · “Harnessing the power of data and AI at Kenvue equips our teams to accelerate product development, optimise decisions, and create seamless, ...Missing: headquarters | Show results with:headquarters
  30. [30]
    Kenvue: Holistic, Agile, Digitally-Driven Supply Chain
    Mar 18, 2025 · Michael Altman, Head of Global Strategic Initiatives at Kenvue, talks supply chain transformation, resilience, and learning the lessons of the pandemic.Missing: employees | Show results with:employees
  31. [31]
    Meri Stevens | Supply Chain Magazine
    Mar 4, 2025 · Meri Stevens, Chief Operations Officer at Kenvue, reveals the challenges of separating from J&J and explains how digital capabilities are ...Missing: headquarters | Show results with:headquarters<|separator|>
  32. [32]
    Kenvue's 'Our Vue Forward' Plan Leans Into IT Upgrades
    May 8, 2024 · The expected $275 million program costs will be allocated to upgrading their IT infrastructure for faster and better decision making.
  33. [33]
    [PDF] Kenvue, Inc. (KVUE)
    Nov 7, 2024 · We are also on track to deliver $350 million in annual savings by 2026 through the Our Vue Forward initiative as we continue to modernize our ...
  34. [34]
    Kenvue at 2025 dbAccess Conference: Strategic Growth and ...
    Jun 3, 2025 · Operational Updates. Separation from J&J: Kenvue completed the exit from over 2,300 TSAs, finalizing its separation from Johnson & Johnson.
  35. [35]
    Kenvue holds ribbon cutting ceremony for new HQ featuring Insights ...
    Mar 19, 2025 · An Insights Lab, a high tech, multi-room experience, is designed to transform how Kenvue develops, tests, and showcases its products. A Virtual ...Missing: employees | Show results with:employees
  36. [36]
    How digital tech transforms supply ops at Kenvue - LinkedIn
    Jun 11, 2025 · How can digital technology fundamentally transform supply operations – and help us at Kenvue deliver care to millions around the world?Missing: headquarters employees independence
  37. [37]
    Tylenol maker Kenvue fires CEO Thibaut Mongon - CNBC
    Jul 14, 2025 · Kenvue has fired CEO Thibaut Mongon, who also stepped down from the board, the consumer health company said on Monday, marking its second major ...
  38. [38]
    Kenvue Announces CEO Transition and Actions to Unlock ...
    Jul 14, 2025 · Kenvue Announces CEO Transition and Actions to Unlock Shareholder Value · Appoints Current Kenvue Director and Proven CPG and Technology Company ...
  39. [39]
    Tylenol maker Kenvue ousts CEO amid board's strategic review
    Jul 14, 2025 · Kenvue named director Kirk Perry as interim CEO, while Mongon also stepped down from the board. Perry, who worked at Procter & Gamble (PG.N) , ...
  40. [40]
    Kenvue Announces CEO Transition and Actions to Unlock ...
    Jul 14, 2025 · The Board has appointed Mr. Kirk Perry as Interim Chief Executive Officer, effective immediately. Mr. Perry is a current Kenvue director and ...<|separator|>
  41. [41]
    KVUE - Kenvue Inc Executives - Morningstar
    ; Amit Banati (56) Chief Financial Officer, —, — ; Carlton Lawson (56) Group President, ...
  42. [42]
    Kenvue Inc. (KVUE) Leadership & Management Team Analysis
    Leadership Team ; Kirk PerryInterim CEO & Director ; Meredith StevensChief Operations Officer ; Carlton LawsonGroup President of EMEA & Latin America ; Amit Banati ...
  43. [43]
    Our story and leadership team | Kenvue - A new view of care
    Learn about our leadership team who believe that when people can count everyday care, it not only makes them well, it makes them whole.
  44. [44]
    Leadership Team - Kenvue - The Org
    The Leadership Team at Kenvue guides the strategic direction and operational excellence of the company in the consumer health sector.
  45. [45]
    [PDF] 2025 Proxy Statement
    Apr 9, 2025 · The Board has nominated the 13 individuals listed below for election as directors at this Annual Meeting to serve until the next annual meeting ...
  46. [46]
    Kenvue Announces Three New Appointments to Board of Directors
    Mar 5, 2025 · With these appointments, the Board will temporarily expand from 11 to 14 directors, and as of the 2025 Annual Meeting of Shareholders, the ...
  47. [47]
    Press Release dated March 5, 2025 - SEC.gov
    Mar 5, 2025 · “We are pleased to welcome Sarah, Erica and Jeff as new directors on Kenvue's Board,” said Larry Merlo, Chair of Kenvue's Board. “Sarah's ...
  48. [48]
    Starboard nominates four directors to Kenvue's board | Reuters
    Feb 5, 2025 · Kenvue's current board has 11 members, each of whose term is set to expire at the company's annual meeting later this year. The hedge fund said ...
  49. [49]
    [PDF] KENVUE INC. PRINCIPLES OF CORPORATE GOVERNANCE We ...
    It is our goal that at least a majority of our directors be “independent,” not only as that term may be defined legally or mandated by the New York Stock ...
  50. [50]
    Governance - Kenvue Inc. - Investor Relations
    Code of Business Conduct and Ethics for Members of the Board of Directors and Executive Officers PDF Format (opens in new window) 82 KBMissing: NYSE | Show results with:NYSE
  51. [51]
    Kenvue reports second quarter 2025 results - A new view of care
    Aug 7, 2025 · ... Our Vue Forward, as well as quarterly phasing of brand support. Interest Expense, Net and Taxes. Second quarter 2025 Interest expense, net ...
  52. [52]
    Kenvue - SEC.gov
    This is an initial public offering of shares of the common stock of Kenvue Inc. We are offering shares of our common stock to be sold in this offering.<|separator|>
  53. [53]
    [PDF] 2024 Annual Report
    This Annual Report on Form 10-K and Kenvue Inc. ... Beginning in the fiscal twelve months ended December 29, 2024, under the Kenvue Plan, the Company grants PSUs ...
  54. [54]
    Our locations - A new view of care - Kenvue
    Dive deeper into local news & resources · Brazil · Argentina · Central America · Chile · Colombia · Germany · India.
  55. [55]
    Kenvue - SEC.gov
    With a global team of more than 22,000 employees, presence in more than 165 countries and 25 in-house manufacturing sites, we are the world's largest pure-play ...
  56. [56]
    Tylenol's 70-year history: From kids' drug to political controversy
    Sep 25, 2025 · It's been 70 years since Philadelphia-based McNeil Laboratories introduced the first pure acetaminophen product to American consumers: ...
  57. [57]
    Happy Birthday, Tylenol! - Pharmacy Times
    Dec 1, 2005 · The brand's sales were up nearly9% in the first 9 months of 2005.Sales in 2004 totaled $786.5 million,but the figure does not include sales ...<|separator|>
  58. [58]
    Kenvue Stock Recoups Losses After Trump Links Tylenol to Autism
    Sep 23, 2025 · Kenvue's self-care segment, which includes Tylenol, Motrin, Benadryl, and other medications, generated about 42% of the company's sales last ...
  59. [59]
    Skin Health | Samples, Products & Resources | Kenvue Professional
    Help support their skin health with science-backed resources from trusted Kenvue brands, Neutrogena and Aveeno.
  60. [60]
    Kenvue Brand - Health & Personal Care Products - Kroger
    Free delivery over $35 30-day returnsFind a wide variety of health and personal care products from Kenvue , including skin care, baby bath and skin care, oral care, OTC medication and first aid ...
  61. [61]
    Kenvue Research and Development Expenses 2020-2025 | KVUE
    Kenvue annual research and development expenses for 2024 were $0.185B, a 0% decline from 2023. Kenvue annual research and development expenses for 2023 were ...
  62. [62]
    Science in action: Kenvue research driving real-life solutions
    Jul 17, 2025 · This year, 14 clinical studies from Kenvue Skin Health & Beauty brands, including Neutrogena, Aveeno, NeoStrata, and Lubriderm, focused on skin ...Missing: Tylenol | Show results with:Tylenol
  63. [63]
    Kenvue to Showcase New Clinical Data on Skin Longevity ...
    Mar 7, 2025 · In findings from the 14 clinical studies detailing new Kenvue scientific research, the Company will present evidence alongside industry experts ...
  64. [64]
    4 Kenvue clinical studies that helped us earn trust with science
    Nov 11, 2024 · Our scientists have conducted more than 500 clinical studies, all of which help to deliver safe, effective, everyday care at every stage of life.Missing: innovation Tylenol
  65. [65]
    From brand innovation to key moments of everyday care - Kenvue
    Jan 2, 2025 · From allergy medicine that melts in your mouth to the European launch of one of our favorite Kenvue brands, here are a few of the moments that made our year.
  66. [66]
    Maintain healthy practice - A new view of care - Kenvue
    Jun 26, 2025 · Sustainable Innovation Profiler. In 2024, we piloted our Sustainable Innovation Profiler, a patent-pending product sustainability assessment ...
  67. [67]
    How Kenvue gets its product designers thinking more environmentally
    Jul 23, 2025 · The company behind Tylenol and Neutrogena is rolling out a digital dashboard for R&D employees.
  68. [68]
    Kenvue announces 5-year collaboration with Microsoft to transform ...
    Apr 16, 2025 · Kenvue is already piloting the use of systems and tools that integrate Microsoft Azure AI, Microsoft 365 Copilot, and Copilot Studio, in ...
  69. [69]
    Albert Invent Partners with Kenvue to Build the Future of Consumer ...
    Oct 14, 2025 · Frontier AI company Albert Invent today announced a strategic partnership with Kenvue Inc. (NYSE: KVUE), maker of consumer health products ...
  70. [70]
    J&J's Kenvue prices upsized IPO at upper end of range to raise $3.8 ...
    May 3, 2023 · Reuters was first to report that Kenvue's IPO will be priced at $22 per share. While the Kenvue deal is the largest IPO to launch since ...
  71. [71]
    J&J Kenvue IPO: KVUE starts trading on NYSE - CNBC
    May 4, 2023 · Shares of Johnson & Johnson 's consumer-health spinoff Kenvue jumped 22% Thursday after its market debut on the New York Stock Exchange.<|separator|>
  72. [72]
    J&J's consumer health spinoff Kenvue begins trading at $25.53 per ...
    May 4, 2023 · ... consumer health spinoff Kenvue begins trading at $25.53 per share. J&J's consumer health IPO Kenvue opens to the NYSE. 06:42. Thu, May 4 20231:37 PM EDT ...
  73. [73]
    Kenvue Shares Jump on First Day of Trading - Investopedia
    May 4, 2023 · Following IPO pricing of $22 per share, Kenvue stock closed its first trading session at $26.90, marking gains of 22%. Shares of Kenvue soared ...
  74. [74]
    Johnson & Johnson Offers Exchange for Shares of Spinoff Kenvue
    Jul 24, 2023 · J&J shareholders will have the choice to exchange all, some, or none of their common stock shares with Kenvue's shares at a 7% discount.
  75. [75]
    Kenvue Initiates Quarterly Cash Dividend
    Jul 20, 2023 · The third quarter dividend is payable on September 7, 2023 ... Kenvue also today announced its financial results for the second quarter ending ...Missing: post IPO yield
  76. [76]
    Kenvue Inc (KVUE) Q1 2025 Earnings Call Highlights - Yahoo Finance
    May 9, 2025 · Revenue Growth Outlook for 2025: 2% to 4% organic sales growth expected. Tariff Impact: Estimated $150 million impact for 2025 due to tariffs ...
  77. [77]
    Kenvue Reports Second Quarter 2025 Results
    Aug 7, 2025 · Separation-related costs are composed of the following: Fiscal Three Months Ended. Fiscal Six Months Ended. (Unaudited; Dollars in Millions).
  78. [78]
    Kenvue Cuts Outlook on Weak Demand as Brand Review Continues
    Aug 7, 2025 · Kenvue Inc. slashed its full-year sales target as demand continued to deteriorate, with organic sales now seen falling by a low-single digit ...
  79. [79]
    [PDF] Kenvue, Inc. (KVUE)
    Aug 7, 2025 · Organic sales for essential health decreased 2.4% as volume and value realization contracted 1.8% and 0.6% respectively. In addition to cycling ...
  80. [80]
    KVUE: Kenvue Inc - Stock Price, Quote and News - CNBC
    Key Stats · Market Cap27.936B · Shares Out1.87B · 10 Day Average Volume33.61M · Dividend0.83 · Dividend Yield5.55% · Beta0.66 · YTD % Change-29.93.Missing: performance | Show results with:performance<|separator|>
  81. [81]
    Kenvue Inc. (KVUE) Stock Price, News, Quote & History
    Kenvue Inc. operates as a consumer health company in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America.
  82. [82]
    Kenvue Q2: Sliding Sales Signals Shifting Consumer Demand
    Aug 14, 2025 · Key Takeaways:Net sales fell 4.0% in Q2; organic sales down 4.2% amid softer seasonal demand.Gross margins compressed due to inflation, ...
  83. [83]
    Company Investigation Confirms No Asbestos in Johnson's Baby ...
    Dec 3, 2019 · Johnson & Johnson Consumer Inc. (the Company) today reaffirmed that its Johnson's Baby Powder is safe and free of asbestos after a comprehensive investigation.
  84. [84]
    15 New Tests from the Same Bottle of Johnson's Baby Powder ...
    Oct 29, 2019 · 15 new tests from the same bottle of Johnson's Baby Powder previously tested by the US Food and Drug Administration (FDA) found no asbestos.<|control11|><|separator|>
  85. [85]
    Acetaminophen Use During Pregnancy and Children's Risk of ...
    Apr 9, 2024 · Findings In this population-based study, models without sibling controls identified marginally increased risks of autism and attention-deficit/ ...
  86. [86]
    Study reveals no causal link between neurodevelopmental ... - NIH
    Apr 11, 2024 · Acetaminophen exposure during pregnancy is not linked to the risk of developing autism, ADHD, or intellectual disability, according to a new study.
  87. [87]
    Acetaminophen - FDA
    Aug 14, 2025 · This is a consumer webpage focused on the safe use of over-the-counter acetaminophen-containing products.Missing: GRASE | Show results with:GRASE
  88. [88]
    Trends in rates of acetaminophen-related adverse events ... - PubMed
    Results: Rates of poison center calls with acetaminophen-related exposures decreased from 49.5/1000 calls in 2009 to 43.5/1000 calls in 2012. Rates of emergency ...
  89. [89]
    https://www.accessdata.fda.gov/scripts/cder/omuf/index.cfm
  90. [90]
    NEUTROGENA ULTRA SHEER FACE AND BODY SUNSCREEN ...
    Packager: Kenvue Brands LLC. Category: HUMAN OTC DRUG LABEL; DEA Schedule: None. Drug Label Information. Updated March 20, 2025. If you are a consumer or ...
  91. [91]
    Position on quality, safety and compliance - A new view of care
    Kenvue aims for end-to-end quality and safety, driven by a CEO, using Quality System Principles, and ensuring compliance with regulations and standards.
  92. [92]
    https://www.ainvest.com/news/navigating-regulatory-crosscurrents-kenvue-strategic-engagement-fda-safeguard-flagship-brands-2510/
  93. [93]
    [PDF] NDA 019835/S-052 SUPPLEMENT APPROVAL Kenvue Brands LLC
    Mar 25, 2025 · We remind you that you must comply with reporting requirements for an approved NDA. (21 CFR 314.80 and 314.81). 1 We update guidances ...
  94. [94]
    https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRL/rl.cfm?lid=461661&lpcd=IMD
  95. [95]
    J&J faces first UK lawsuits alleging its baby powder caused cancer
    Oct 16, 2025 · The firm says J&J's talc products contained carcinogenic fibres, including asbestos, which has been linked to deadly mesothelioma. J&J has long ...
  96. [96]
    J&J Ordered to Pay $45M in Talc Baby Powder Lawsuit
    Apr 29, 2024 · An Illinois jury's verdict orders defendants Johnson & Johnson and Kenvue to pay $45 million to the family of a woman who died of mesothelioma.
  97. [97]
    J&J And Kenvue Must Pay $45 Million In Talcum Baby Powder Lawsuit
    Apr 20, 2024 · An Illinois court late Friday ordered pharmaceutical giant Johnson & Johnson and Kenvue to pay $45 million to a family that alleged the companies' talcum-based ...
  98. [98]
    A systematic review of the epidemiology evidence on talc and cancer
    Therefore, epidemiology studies do not provide evidence supporting a causal association between talc exposures and ovarian cancer risk. Endometrial/uterine ...
  99. [99]
    Perineal Talc Use and Ovarian Cancer: A Critical Review - PMC
    Several studies conducted over the past 25 years found an association between perineal talc powders and ovarian cancer. The summary relative risk is about 1.3 ( ...
  100. [100]
    Talcum Powder and Cancer
    Aug 1, 2024 · IARC classifies talc as “p robably carcinogenic to humans ,” based on “limited” evidence for (ovarian) cancer in humans, “sufficient” evidence ...Missing: regulatory | Show results with:regulatory
  101. [101]
    Screening assessment talc - Canada.ca
    Apr 22, 2021 · Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer.
  102. [102]
    Thousands in UK sue Johnson & Johnson over talcum powder ...
    Oct 16, 2025 · The claim cites internal documents, which it says show J&J advocated for talc testing standards that tolerated up to 1% asbestos contamination, ...
  103. [103]
    Johnson & Johnson Sued in U.K. Over Baby Powder Cancer Claims
    Oct 16, 2025 · The talc used in baby power “was compliant with any required regulatory standards, did not contain asbestos and does not cause cancer.” The ...
  104. [104]
    Thousands in UK take legal action against Johnson & Johnson over ...
    Oct 16, 2025 · High court claim says company knowingly sold product containing asbestos and 'concealed' risk to public.Missing: purity | Show results with:purity
  105. [105]
    FDA Responds to Evidence of Possible Association Between Autism ...
    Sep 22, 2025 · The U.S. Food and Drug Administration today initiated the process for a label change for acetaminophen (Tylenol and similar products) to ...Missing: GRASE | Show results with:GRASE
  106. [106]
    FACT: Evidence Suggests Link Between Acetaminophen, Autism
    Sep 22, 2025 · The Trump Administration does not believe popping more pills is always the answer for better health. There is mounting evidence finding a ...
  107. [107]
    President Trump, Secretary Kennedy Announce Bold Actions to ...
    Sep 22, 2025 · President Donald J. Trump and Secretary Robert F. Kennedy, Jr. announced bold new actions to confront the nation's autism spectrum disorder ...Missing: warning | Show results with:warning
  108. [108]
    Lawsuits against Tylenol's maker get a boost after Trump's comments
    Sep 29, 2025 · Keller says he filed what was among the first lawsuits alleging that prenatal acetaminophen exposure caused autism or ADHD. But in 2023, a ...
  109. [109]
    Attorneys Urge Court Overseeing Tylenol Autism Lawsuits to ...
    Sep 26, 2025 · A judge last year dismissed hundreds of lawsuits alleging a connection between Tylenol or generic versions of the drug and autism or ADHD ...<|separator|>
  110. [110]
    Tylenol ADHD & Autism Lawsuits - Drugwatch.com
    Lawsuits against the maker of Tylenol claim the product can cause autism and ADHD in children if taken when a person is pregnant. Learn more.
  111. [111]
    Kenvue position on acetaminophen (Tylenol®) and autism claims
    We believe independent, sound science clearly shows that taking acetaminophen does not cause autism. We strongly disagree with allegations that it does and are ...
  112. [112]
    https://www.reuters.com/business/healthcare-pharmaceuticals/kenvue-urges-us-fda-deny-request-tylenols-autism-warning-2025-10-20/
  113. [113]
    Research shows no causal link between Tylenol and autism
    Apr 17, 2024 · A new study from JAMA found that using acetaminophen, the active ingredient in Tylenol, during pregnancy was not associated with increased risk of autism, ADHD ...
  114. [114]
    ACOG Affirms Safety Benefits Acetaminophen Pregnancy
    Sep 22, 2025 · "The data from numerous studies have shown that acetaminophen plays an important—and safe—role in the well-being of pregnant women."
  115. [115]
    https://www.aap.org/en/news-room/fact-checked/acetaminophen-is-safe-for-children-when-taken-as-directed-no-link-to-autism/
  116. [116]
    WHO statement on autism-related issues
    Sep 24, 2025 · The World Health Organization (WHO) emphasizes that there is currently no conclusive scientific evidence confirming a possible link between ...Missing: consensus | Show results with:consensus
  117. [117]
    Kenvue: This Too Shall Pass (NYSE:KVUE) | Seeking Alpha
    Sep 24, 2025 · Kenvue shares have dropped 17% following reports linking Tylenol to autism, creating a potential long-term buying opportunity.
  118. [118]
    Kenvue stock drops 10% on RFK Jr. Tylenol autism report - CNBC
    Sep 5, 2025 · Kenvue stock drops 10% on report RFK Jr. will link autism to Tylenol use during pregnancy · Shares of Kenvue fell more than 10% on Friday after a ...
  119. [119]
    Tylenol-maker Kenvue shares bounce back, Trump claims ... - Reuters
    Sep 23, 2025 · September 23, 20253:13 PM PDTUpdated September 23, 2025 ... Kenvue stock has fall 20% so far this year. Many doctors reject the claim, and ...
  120. [120]
    Trump's Tylenol advice: What should parents do? : Shots - NPR
    Sep 23, 2025 · The Trump administration has linked use of the painkiller acetaminophen during pregnancy to autism. Here's what the science, and doctors, have ...
  121. [121]
    Evaluation of the evidence on acetaminophen use and ...
    Aug 14, 2025 · Acetaminophen is the most commonly used over-the-counter pain and fever medication taken during pregnancy, with > 50% of pregnant women ...
  122. [122]
    [PDF] Notice to Physicians on the Use of Acetaminophen During Pregnancy
    Sep 22, 2025 · Some studies have described that the risk may be most pronounced when acetaminophen is taken chronically throughout pregnancy to childbirth.Missing: GRASE | Show results with:GRASE
  123. [123]
    How the Tylenol murders of 1982 changed the way we consume ...
    Sep 29, 2014 · For example, Johnson & Johnson quickly established that the cyanide lacing occurred after cases of Tylenol left the factory. Someone, police ...
  124. [124]
    James Lewis, the suspect in the 1982 Tylenol poisonings that killed ...
    Jul 10, 2023 · Lewis served more than 12 years in prison for sending an extortion note to manufacturer Johnson & Johnson, demanding $1 million to “stop the ...
  125. [125]
    Tragedy, then triumph: How Johnson & Johnson made sure Tylenol ...
    Oct 27, 2022 · Johnson & Johnson held a nationwide news conference via satellite on Nov. 11, 1982, to announce Tylenol's new tamper-resistant packaging.
  126. [126]
    Tylenol Murders Documentary Tells True Story of Cyanide-Laced Pills
    May 8, 2025 · The families of the Chicago victims sued Johnson & Johnson in 1983, claiming that the company knew that their bodies could be tampered with; ...Missing: Kenvue | Show results with:Kenvue
  127. [127]
    Beyer v. Kenvue Brands LLC | Law.com Radar
    Jun 26, 2025 · Kenvue Brands was hit with a consumer class action on June 26 in New Jersey District Court over allegedly false marketing of Aveeno-brand ...
  128. [128]
    Kenvue Inc. | The ClassAction.org Legal News Wire
    November 7, 2024 A federal judge has dismissed a class action that alleged retailers and manufacturers misled consumers by marketing over-the-counter medicines ...<|separator|>
  129. [129]
    The Company Behind Tylenol Tries to Navigate Its Latest Crisis
    Sep 22, 2025 · Even with the generic competition, Tylenol still generates roughly $1 billion in annual sales for Kenvue, according to an estimate from ...